Misplaced Pages

Estradiol benzoate butyrate /
algestone acetophenide

Estradiol benzoate butyrate (top) and algestone acetophenide (bottom)
Combination of
Estradiol benzoate butyrate	Estrogen
Algestone acetophenide	Progestogen
Clinical data
Trade names	Neolutin N, Redimen, Soluna, Unijab
Other names	Estradiol benzoate butyrate/dihydroxyprogesterone acetophenide; EBB/DHPA; Unimens
Routes of administration	Intramuscular injection

Estradiol benzoate butyrate/algestone acetophenide, also known as estradiol benzoate butyrate/dihydroxyprogesterone acetophenide (EBB/DHPA) and sold under the brand names Neolutin N, Redimen, Soluna, and Unijab, is a form of combined injectable birth control which is used in Peru and Singapore. It contains estradiol benzoate butyrate (EBB), an estrogen, and algestone acetophenide (dihydroxyprogesterone acetophenide; DHPA), a progestin. The medication is given once per month by injection into muscle.

Medical uses

EBB/DHPA is used as a once-a-month combined injectable contraceptive to prevent pregnancy in women.

Available forms

EBB/DHPA contains 10 mg estradiol benzoate butyrate (EBB), an estrogen, and 150 mg algestone acetophenide (dihydroxyprogesterone acetophenide; DHPA), a progestin.

Pharmacology

Pharmacodynamics

EBB/DHPA has been said to have relatively weak estrogenic activity and has been described as "progestogen-dominant".

Pharmacokinetics

EBB is said to have a shorter duration than estradiol enantate of about 3 weeks. EBB/DHPA was developed because it was thought that the duration of EBB would be more suitable for use as a once-monthly combined injectable contraceptive than estradiol enantate in estradiol enantate/algestone acetophenide.

Society and culture

Brand names

EBB/DHPA is marketed under the brand names Neolutin N, Redimen, Soluna, and Unijab. It was originally developed under the tentative brand name Unimens, but ultimately was not marketed under this particular brand name.

Availability

EBB/DHPA is available only in Peru and Singapore.

See also

• Combined injectable birth control § Available forms
• Estradiol enantate/algestone acetophenide
• List of combined sex-hormonal preparations

References

1. ^ Toppozada M (June 1977). "The clinical use of monthly injectable contraceptive preparations". Obstet Gynecol Surv. 32 (6): 335–47. doi:10.1097/00006254-197706000-00001. PMID 865726.
2. ^ IARC Working Group on the Evaluation of Carcinogenic Risks to Humans; World Health Organization; International Agency for Research on Cancer (2007). Combined Estrogen-progestogen Contraceptives and Combined Estrogen-progestogen Menopausal Therapy. World Health Organization. pp. 433, 467. ISBN 978-92-832-1291-1.
3. ^ IARC Working Group on the Evaluation of Carcinogenic Risks to Humans; International Agency for Research on Cancer (1 January 1999). Hormonal Contraception and Post-menopausal Hormonal Therapy (PDF). IARC. p. 65. ISBN 978-92-832-1272-0. Archived from the original (PDF) on 28 August 2021. Retrieved 16 September 2018.
4. ^ "Farmaco SOLUNA 150 + 10 registrado en Perú".
5. ^ "Unijab Dosage & Drug Information | MIMS Singapore".
6. ^ "SOLUNA". www.corporacionmisalud.com. Archived from the original on 2014-10-05.
7. ^ Mokhtar K. Toppozada (1983). "Monthly Injectable Contraceptives". In Alfredo Goldsmith; Mokhtar Toppozada (eds.). Long-Acting Contraception. pp. 93–103. OCLC 35018604.
8. "Archived copy". Archived from the original on 2019-02-25. Retrieved 2019-02-25.{{cite web}}: CS1 maint: archived copy as title (link)
9. Elsayed Saad Eldin Hafez (1980). Human reproduction: conception and contraception. Harper and Row. ISBN 978-0-06-141066-6.
10. Newton JR, D'arcangues C, Hall PE (1994). "A review of "once-a-month" combined injectable contraceptives". J Obstet Gynaecol (Lahore). 4 Suppl 1: S1–34. doi:10.3109/01443619409027641. PMID 12290848.
11. Toppozada MK (April 1994). "Existing once-a-month combined injectable contraceptives". Contraception. 49 (4): 293–301. doi:10.1016/0010-7824(94)90029-9. PMID 8013216.

• Medicine

• Combined injectable contraceptives